FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns using a compound representing 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine or its salt for producing a pharmaceutical composition applicable for treating hyperproliferative diseases responding to FAP (fibroblast activator protein) inhibition specified in a group consisting cirrhosis, or healing wounds, treating acne and proliferative skin diseases, such as e.g. psoriasis.
EFFECT: invention refers to using the substances, which possess an inhibitory ability for treating hyperproliferative diseases.
4 cl
| Title | Year | Author | Number |
|---|---|---|---|
| XANTHIC DERIVATIVE | 2013 |
|
RU2635109C2 |
| XANTHINE DERIVATIVE | 2016 |
|
RU2709348C2 |
| THERAPEUTIC ANTIDIABETIC AGENT | 2006 |
|
RU2438671C2 |
| COMBINED PRODUCTS CONTAINING TYROSINE KINASE INHIBITORS AND THEIR USE | 2013 |
|
RU2660354C2 |
| CRYSTALLINE FORM OF ORGANIC COMPOUND | 2009 |
|
RU2572529C2 |
| COMPOUNDS WITH CONDENSED 1,3-DIHYDROIMIDAZOLE CYCLE | 2003 |
|
RU2328498C9 |
| ANTICANCER AGENT | 2016 |
|
RU2729936C2 |
| AMINOMETHYL QUINOLONES USEFUL IFOR TREATMENT OF JNK-MEDIATED DISORDER | 2012 |
|
RU2629111C2 |
| IDENTIFICATION OF LKB1 MUTATION AS PROGNOSTIC BIOMARKER OF SENSITIVITY TO TOR-KINASE INHIBITORS | 2011 |
|
RU2565034C2 |
| METHODS AND COMPOSITIONS TO IMPROVE COGNITIVE FUNCTIONS | 2012 |
|
RU2792010C2 |
